Zanolimumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) →References: Page already in Cat:Monoclonal antibody stubs using AWB |
Anypodetos (talk | contribs) Added mab_type, updated source |
||
| Line 2: | Line 2: | ||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| |
| mab_type = mab |
||
| source = u |
|||
| target = [[CD4]] |
| target = [[CD4]] |
||
| CAS_number = 652153-01-0 |
| CAS_number = 652153-01-0 |
||
Revision as of 15:43, 24 March 2010
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | 147 kDa |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, cutaneous and peripheral T-cell lymphoma.[2][3]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |